- Home
- SFL vs VRDN Comparison
SFL vs VRDN Comparison
Compare SFL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- VRDN
- Stock Information
- Founded
- SFL 2003
- VRDN 2006
- Country
- SFL Bermuda
- VRDN United States
- Employees
- SFL N/A
- VRDN N/A
- Industry
- SFL Marine Transportation
- VRDN Medical Specialities
- Sector
- SFL Consumer Discretionary
- VRDN Health Care
- Exchange
- SFL Nasdaq
- VRDN Nasdaq
- Market Cap
- SFL 1.1B
- VRDN 1.2B
- IPO Year
- SFL N/A
- VRDN N/A
- Fundamental
- Price
- SFL $8.74
- VRDN $14.73
- Analyst Decision
- SFL Strong Buy
- VRDN Strong Buy
- Analyst Count
- SFL 1
- VRDN 11
- Target Price
- SFL $13.00
- VRDN $38.50
- AVG Volume (30 Days)
- SFL 1.1M
- VRDN 750.4K
- Earning Date
- SFL 08-13-2025
- VRDN 08-07-2025
- Dividend Yield
- SFL 12.15%
- VRDN N/A
- EPS Growth
- SFL N/A
- VRDN N/A
- EPS
- SFL 0.41
- VRDN N/A
- Revenue
- SFL $852,590,000.00
- VRDN $302,000.00
- Revenue This Year
- SFL N/A
- VRDN N/A
- Revenue Next Year
- SFL $3.20
- VRDN $17,102.33
- P/E Ratio
- SFL $21.91
- VRDN N/A
- Revenue Growth
- SFL 6.58
- VRDN 4.86
- 52 Week Low
- SFL $6.78
- VRDN $9.90
- 52 Week High
- SFL $14.14
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- SFL 58.71
- VRDN 54.65
- Support Level
- SFL $8.66
- VRDN $14.31
- Resistance Level
- SFL $8.98
- VRDN $16.05
- Average True Range (ATR)
- SFL 0.21
- VRDN 0.78
- MACD
- SFL 0.00
- VRDN -0.01
- Stochastic Oscillator
- SFL 58.00
- VRDN 50.18
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).